| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.5 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.5 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.038 | 0.5 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.5 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |